· Administration of all 12 subjects was completed in the Phase 1 clinical trial of injectable knee osteoarthritis cell therapy product
· Advanced cell culture technology with large-scale manufacturing of highly efficient stem cells
MEDIPOST, a leading stem cell biotechnology company, today announced the completion of administration of all subject in the phase 1 clinical study of intra-articular injectable knee osteoarthritis cell therapy product, which is being development as second-generation stem cell therapy product for knee osteoarthritis.
The phase 1 study, where 12 mild to moderate knee OA patients are assigned into three dosing groups (3 for low-dose, 3 for mid-dose and 6 for high-dose), is designed to evaluate the safety and efficacy of the cell therapy product (code name: SMUP-IA-01).
The study subjects will be observed for six months following a single intra-articular injection of the cell therapy product. In addition, the study subjects will be monitored for a further 5-year period as part of the long-term follow-up study, which was initiated last month.
During the past several years, MEDIPOST has been accelerating efforts to advance its SMUP-Cell platform technology for developing next-generation cell therapy products including injectable osteoarthritis product.
The SMUP-Cell platform technology enables selection of small-sized highly-efficient stem cells and mass-culture under specific environment and conditions which enhance stem cell properties and functionality.
“Despite concerns over the current COVID-19 pandemic situation, patient enrollment and administration of SMUP-IA-01 cell therapy product progressed smoothly as planned which reflects the high anticipation from the patients suffering from the knee osteoarthritis” said a MEDIPOST official, adding “We expect to complete the ongoing clinical trial by end of this year.”